Sernova Corp

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP
81732W104
SEDOL
N/A
CIK
N/A
sernova.com
LEI:
©
FIGI: BBG000CDMG98
SVA
Sernova Corp
GICS: - · Sector: - · Sub-Sector: -
AI
PROFILER
NAME
Sernova Corp
ISIN
CA81732W1041
TICKER
SVA
MIC
XTSE
REUTERS
SVA.TO
BLOOMBERG
SVA CN
BUILD THEMEFOLIO SHARE IDEAS DISCUSS
LEVERAGE INVEST
EN 728x90
Financial Intelligence
360° iHub Crowd iFeed ATH Tracker Index Tracker ETF TF Spicy2 X-Billboard
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants
EQS Newswire is a major provider of regulatory and corporate news. It mainly serves companies, investors and media worldwide. Through its services, EQS Newswire enables efficient and secure communication between companies and their stakeholders. Its main services include the distribution of ad hoc announcements, corporate news and the publication of financial reports that meet strict international standards.
Fri, 27.09.2024

Original-Research: Sernova Corp - from First Berlin Equity Research GmbH 27.09.2024 / 12:41 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude ce...
Research & Analysis
Read more
Tue, 06.02.2024

Original-Research: Sernova Corp - von First Berlin Equity Research GmbH Einstufung von First Berlin Equity Research GmbH zu Sernova Corp Unternehmen: Sernova Corp ISIN: CA81732W1041 Anlass der Studie: Update Empfehlung: Buy seit: 06.02.2024 Kursziel: CAD 3.80 Kursziel auf Sicht von: 12 months Letzte Ratingänderung: - Analyst: Christian Orquera Fir...
Research & Analysis
Read more
Thu, 19.10.2023

Original-Research: Sernova Corp - von First Berlin Equity Research GmbH Einstufung von First Berlin Equity Research GmbH zu Sernova Corp Unternehmen: Sernova Corp ISIN: CA81732W1041 Anlass der Studie: Initiating coverage Empfehlung: BUY seit: 19.10.2023 Kursziel: CAD3.80 Kursziel auf Sicht von: 12 months Letzte Ratingänderung: - Analyst: Christian...
Research & Analysis
Read more
Thu, 14.09.2023

LONDON, Ontario; WINDHAM COUNTY, Connecticut – September 14, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it has rescheduled the investor and analyst conference call previously scheduled for September 15 at 10 a.m. Eastern Time. The call will now occur on Sep...
Research & Analysis
Read more
Wed, 13.09.2023

- Introduction of New CEO Cynthia Pussinen and Recently Appointed Chief Business Officer, Dr. Modestus Obochi, on September 15, 2023 - - Business Update, Strategy & Outlook Call on October 5, 2023 - LONDON, Ontario; WINDHAM COUNTY, Connecticut – September 13, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage compa...
Research & Analysis
Read more
Wed, 03.05.2023

LONDON, Ontario – May 3, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it has entered into a preclinical research collaboration with AstraZeneca (LSE/STO/Nasdaq:AZN) to evaluate the use of Sernova’s Cell Pouch System™ in combination with AstraZeneca’s novel th...
Research & Analysis
Read more
Wed, 03.05.2023

LONDON, Ontario – May 3, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it has entered into a preclinical research collaboration with AstraZeneca (LSE/STO/Nasdaq:AZN) to evaluate the use of Sernova’s Cell Pouch System™ in combination with AstraZeneca’s novel th...
Research & Analysis
Read more
Mon, 10.04.2023

LONDON, Ontario – April 10, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced that President and Chief Executive Officer, Dr. Philip Toleikis, will present at the upcoming annual Cell & Gene Meeting on the Med to be held April 12-14, 2023 at the Hotel Arts Bar...
Research & Analysis
Read more
Mon, 10.04.2023

LONDON, Ontario – April 10, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced that President and Chief Executive Officer, Dr. Philip Toleikis, will present at the upcoming annual Cell & Gene Meeting on the Med to be held April 12-14, 2023 at the Hotel Arts Bar...
Research & Analysis
Read more
Wed, 22.03.2023

Sernova Announces Abstract on First Cohort of its Phase 1/2 Study Involving Islet Allotransplantation into Pre-vascularized Cell PouchTM Selected for Oral Podium Presentation at American Diabetes Association 83rd Scientific Sessions 2023 LONDON, Ontario – March 22, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage com...
Research & Analysis
Read more
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S